|
MechanismCSF-2R stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
对头颈癌患者瘤内注射选择性溶瘤重组腺病毒注射液(KH901)的II期临床试验
[Translation] Phase II clinical trial of intratumoral selective oncolytic recombinant adenovirus injection (KH901) in patients with head and neck cancer
观察局部瘤内注射KH901联合全身化疗治疗头颈部肿瘤的有效性,观察局部瘤内注射KH901联合全身化疗的不良反应。
[Translation] To observe the effectiveness of local intratumoral injection of KH901 combined with systemic chemotherapy in the treatment of head and neck tumors, and to observe the adverse reactions of local intratumoral injection of KH901 combined with systemic chemotherapy.
对头颈癌患者瘤内注射特异性溶瘤重组腺病毒注射液(KH901)的I期临床试验
[Translation] Phase I clinical trial of intratumoral injection of specific oncolytic recombinant adenovirus injection (KH901) in patients with head and neck cancer
确定在头颈癌患者局部瘤内注射KH901的安全性,确定最大耐受剂量,推荐Ⅱ期临床试验合理的剂量和用药方案。
[Translation] To determine the safety of local intratumoral injection of KH901 in patients with head and neck cancer, determine the maximum tolerated dose, and recommend a reasonable dose and medication regimen for Phase II clinical trials.
100 Clinical Results associated with Chengdu Phargentech Technology Co Ltd
0 Patents (Medical) associated with Chengdu Phargentech Technology Co Ltd
100 Deals associated with Chengdu Phargentech Technology Co Ltd
100 Translational Medicine associated with Chengdu Phargentech Technology Co Ltd